×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PHAT – phathom pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PHAT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
04:07 pm
phat
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
Low
Report
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]
11/13
12:02 am
phat
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]
Low
Report
Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]
11/4
08:00 am
phat
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Low
Report
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
11/3
07:59 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
10/31
10:07 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.
10/31
07:19 am
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/30
06:06 pm
phat
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Guggenheim.
10/30
07:00 am
phat
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2025
07:00 am
PHAT
phathom pharmaceuticals, inc.
BEAT
Report
-5.2%
phathom pharmaceuticals, inc.
8/7/2025
06:59 am
PHAT
phathom pharmaceuticals, inc.
BEAT
Report
8.1%
phathom pharmaceuticals, inc.
5/1/2025
07:00 am
PHAT
phathom pharmaceuticals, inc.
BEAT
Report
-18.0%
phathom pharmaceuticals, inc.
3/6/2025
08:00 am
PHAT
phathom pharmaceuticals, inc.
BEAT
Report
-3.9%
phathom pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/2
06:45 pm
phat
Form 4 Phathom Pharmaceuticals, For: Nov 28 Filed by: Basta Steven L
Low
Report
Form 4 Phathom Pharmaceuticals, For: Nov 28 Filed by: Basta Steven L
11/5
04:30 pm
phat
Form 4 Phathom Pharmaceuticals, For: Nov 03 Filed by: Breedlove Robert Charles
Low
Report
Form 4 Phathom Pharmaceuticals, For: Nov 03 Filed by: Breedlove Robert Charles
11/4
05:25 pm
phat
Form SCHEDULE 13D/A Phathom Pharmaceuticals, Filed by: Frazier Life Sciences Public Fund, L.P.
Low
Report
Form SCHEDULE 13D/A Phathom Pharmaceuticals, Filed by: Frazier Life Sciences Public Fund, L.P.
11/4
07:05 am
phat
Form 8-K Phathom Pharmaceuticals, For: Nov 04
Low
Report
Form 8-K Phathom Pharmaceuticals, For: Nov 04
11/3
04:22 pm
phat
Form SCHEDULE 13G/A Phathom Pharmaceuticals, Filed by: MILLENNIUM MANAGEMENT LLC
Low
Report
Form SCHEDULE 13G/A Phathom Pharmaceuticals, Filed by: MILLENNIUM MANAGEMENT LLC
10/30
07:06 am
phat
Form 10-Q Phathom Pharmaceuticals, For: Sep 30
Medium
Report
Form 10-Q Phathom Pharmaceuticals, For: Sep 30
10/30
07:00 am
phat
Form 8-K Phathom Pharmaceuticals, For: Oct 30
Medium
Report
Form 8-K Phathom Pharmaceuticals, For: Oct 30
10/27
06:03 am
phat
Form 8-K Phathom Pharmaceuticals, For: Oct 25
Low
Report
Form 8-K Phathom Pharmaceuticals, For: Oct 25
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/3
Form 4 Phathom Pharmaceuticals, For: Apr 01 Filed by: Kolchinsky Peter
13.1%
2/14 Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P. 12.3%
12/23 Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection 11.1%
1/6 Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer 9.6%
10/24 Form S-1MEF Phathom Pharmaceuticals, 9.3%
1/27 Form SC 13D/A Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD 6.9%
12/12 Form 3 Phathom Pharmaceuticals, For: Dec 02 Filed by: Parikh Asit 4.7%
4/9 Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference 2.6%
11/19 Phathom Pharmaceuticals (NASDAQ: PHAT) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 2.4%
11/25 Q3/2019 9/30/2019 EPS -9.300 ZacksConsensus N/A ActVsEst N/A - N/A 2.3%
2/14 Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P. 12.3%
12/23 Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection 11.1%
1/6 Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer 9.6%
10/24 Form S-1MEF Phathom Pharmaceuticals, 9.3%
1/27 Form SC 13D/A Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD 6.9%
12/12 Form 3 Phathom Pharmaceuticals, For: Dec 02 Filed by: Parikh Asit 4.7%
4/9 Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference 2.6%
11/19 Phathom Pharmaceuticals (NASDAQ: PHAT) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 2.4%
11/25 Q3/2019 9/30/2019 EPS -9.300 ZacksConsensus N/A ActVsEst N/A - N/A 2.3%
TOP News Decliners
3/17
Form 8-K Phathom Pharmaceuticals, For: Mar 11
-10.0%
3/20 Phathom Pharmaceuticals (NASDAQ: PHAT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -3.8%
10/26 Phathom Pharmaceuticals goes public [Reuters] -3.5%
3/19 Form 3 Phathom Pharmaceuticals, For: Mar 17 Filed by: Stenhouse Mark -3.3%
3/31 Form 4 Phathom Pharmaceuticals, For: Mar 27 Filed by: Kolchinsky Peter -2.9%
2/6 Form 3/A Phathom Pharmaceuticals, For: Feb 06 Filed by: Kolchinsky Peter -2.5%
11/6 Form SC 13D Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD -2.1%
10/28 Form S-8 Phathom Pharmaceuticals, -1.1%
2/14 Form SC 13G Phathom Pharmaceuticals, Filed by: JANUS HENDERSON GROUP PLC -1.1%
12/2 Form 8-K Phathom Pharmaceuticals, For: Nov 30 -0.9%
3/20 Phathom Pharmaceuticals (NASDAQ: PHAT) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -3.8%
10/26 Phathom Pharmaceuticals goes public [Reuters] -3.5%
3/19 Form 3 Phathom Pharmaceuticals, For: Mar 17 Filed by: Stenhouse Mark -3.3%
3/31 Form 4 Phathom Pharmaceuticals, For: Mar 27 Filed by: Kolchinsky Peter -2.9%
2/6 Form 3/A Phathom Pharmaceuticals, For: Feb 06 Filed by: Kolchinsky Peter -2.5%
11/6 Form SC 13D Phathom Pharmaceuticals, Filed by: TAKEDA PHARMACEUTICAL CO LTD -2.1%
10/28 Form S-8 Phathom Pharmaceuticals, -1.1%
2/14 Form SC 13G Phathom Pharmaceuticals, Filed by: JANUS HENDERSON GROUP PLC -1.1%
12/2 Form 8-K Phathom Pharmaceuticals, For: Nov 30 -0.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: